Title: Atti del 52° Congresso Nazionale: Società Italiana di Igiene, Medicina Preventiva e Sanità Pubblica (SItI) Document date: 2019_10_15
ID: jkke8ije_677
Snippet: The anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, as monotherapy or in combination with chemotherapy, are effective in the treatment of metastatic colorectal cancer (mCRC). Current international guidelines recommend RAS (NRAS, KRAS) genetic testing as predictive biomarkers for response to anti-EGFR therapy. Only RAS wild-type tumors should be treated with anti-EGFR agents, as tumors with RAS mutations are unlikely to benefit.....
Document: The anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, as monotherapy or in combination with chemotherapy, are effective in the treatment of metastatic colorectal cancer (mCRC). Current international guidelines recommend RAS (NRAS, KRAS) genetic testing as predictive biomarkers for response to anti-EGFR therapy. Only RAS wild-type tumors should be treated with anti-EGFR agents, as tumors with RAS mutations are unlikely to benefit. We aimed to review the cost-effectiveness of RAS testing in mCRC patients prior to anti-EGFR therapy and to assess how well economic evaluations adhere to clinical practice guidelines.
Search related documents:
Co phrase search for related documents- genetic testing and RAS testing effectiveness: 1
- genetic testing and wild type: 1, 2
- growth factor and mCRC colorectal cancer: 1
- growth factor and metastatic mCRC colorectal cancer: 1
- growth factor and monoclonal antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30
- growth factor and practice guideline: 1, 2
- growth factor and predictive biomarker: 1, 2, 3
- growth factor and RAS mutation: 1, 2
- growth factor and wild type: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32
- growth factor and wild type tumor: 1, 2
- growth factor receptor and mCRC colorectal cancer: 1
- growth factor receptor and metastatic mCRC colorectal cancer: 1
- growth factor receptor and monoclonal antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- growth factor receptor and practice guideline: 1
- growth factor receptor and predictive biomarker: 1
- growth factor receptor and RAS mutation: 1, 2
- growth factor receptor and wild type: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- growth factor receptor and wild type tumor: 1
- international guideline and practice guideline: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
Co phrase search for related documents, hyperlinks ordered by date